Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology Platform Lungscape Project
Blackhall, Fiona H × Peters, Solange Bubendorf, Lukas Dafni, Urania Kerr, Keith M Hager, Henrik Soltermann, Alex O'Byrne, Kenneth J Dooms, Christophe Sejda, Aleksandra Hernández-Losa, Javier Marchetti, Antonio Savic, Spasenija Tan, Qiang Thunnissen, Erik Speel, Ernst-Jan M Cheney, Richard Nonaka, Daisuke de Jong, Jeroen Martorell, Miguel Letovanec, Igor Rosell, Rafael Stahel, Rolf A #
Grune & Stratton
Journal of Clinical Oncology vol:32 issue:25 pages:2780-7
The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non-small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population.